British Menopause Society consensus statement on the management of estrogen deficiency symptoms,arthralgia and menopause diagnosis in women treated for early breast cancer
Restricted accessReview articleFirst published online March, 2019
British Menopause Society consensus statement on the management of estrogen deficiency symptoms,arthralgia and menopause diagnosis in women treated for early breast cancer
This guidance document by the British Menopause Society provides an overview of the management of women experiencing estrogen deficiency symptoms and arthralgia following a breast cancer diagnosis. It is now recommended that breast cancer patients are referred to health care professionals with an expertise in menopause for the management of such symptoms, which in turn often involves liaison with patients’ breast cancer teams. However, as many women initially present to primary health care professionals for advice, this statement is aimed to support the latter in such consultations by providing information about symptom aetiology, current management strategies and controversies and identifying useful practice points.
NICE. Early and locally advanced breast cancer: diagnosis and treatment. NICE guidance [NG101], July 2018, www.NICE.org.uk(accessed 18 January 2019).
3.
PlevritisSKMunozDKurianAWet al.
Association on screening and treatment with breast cancer mortality by molecular subtype in US women, 2000–2012. JAMA2018;
319:154–164.
4.
MurphyCCBartholomewLCarpentierMet al.
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.Breast Cancer Res Treat2012;
134:459–478.
5.
SantenRJStuenkelCADavisSRet al.
Managing menopausal symptoms and associated clinical issues in breast cancer survivors.J Clin Endocrinol Metab2017;
102: 3647–3661.
6.
BeckweeDLeysenLMeuwisKet al.
Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis.Support Care Cancer2017;
25: 1673–1686.
7.
CruickshankSHumeA.The experience of providing support about menopausal symptoms to breast cancer patients.Eur J Oncol Nurs2014;
18: 110–117.
8.
NICE. Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. Diagnostics guidance [DG10], September 2013, www.NICE.org.uk(accessed 18 January 2019).
CuriglianoGBursteinHJWinerEPet al.
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.Annal Oncol2017;
28: 1700–1712.
11.
National Cancer Survivorship Initiative, www.ncsi.org.uk(accessed 18 January 2019).
12.
Follow-up care – Information and support, www.macmillan.org.uk(accessed 18 January 2019).
13.
MorganAAh-SeeA-LHunterMet al. Comparing clinician and patient perspectives in the management of hot flushes in UK breast cancer patients. NCRI Breast CSG Symptom Management Subgroup. Breast Cancer Res Treat2018. P6.9Abstract 1st Interdisciplinary Breast Cancer Symposium 15–16 January 2018, https://doi.org/10.1007/s10549-017-4585-x(accessed 18 January 2019).
14.
AzimHADavidsonNERuddyKJ.Challenges in treating premenopausal women with endocrine-sensitive breast cancer.Am Soc Clin Oncol Educ Book2016;
35:23–32.
15.
NystedtMBerglundGBolundCet al.
Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study.J Clin Oncol2003;
21:1836–1844.
16.
CellaDFallowfieldLJ.Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.Breast Cancer Res Treat2008;
107:167–180.
17.
FallowfieldLJKilburnLSLangridgeCet al.
Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation.Br J Cancer2012;
106:1062–1067.
18.
LoveRRFeyziJM.Reduction in vasomotor symptoms from tamoxifen over time.J Natl Cancer Inst1993;
85:673–
674.
19.
SearsCSRobinsonJWWalkerLM.A comprehensive review of sexual health concerns after cancer treatment and the biopsychosocial treatment options available to female patientsEur J Cancer Care2018;
27: e12738.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet2015;
386: 1341–1352.
22.
RobinsonPJBellRJChristakisMJet al.
Aromatase inhibitors are associated with low sexual desire causing distress and fecal incontinence in women: an observational study.J Sex Med2017;
14: 1566–1574.
23.
HenryNLAzzouzFDestaZet al:
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.J Clin Oncol2012;
30: 936–942.
24.
CrewKDGreenleeHCapodiceJet al:
Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol2007;
25: 3877–3883.
25.
GaillardSStearnsV.Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res2011;
13: 205.
26.
KyvernatakisIZillerVHarsOet al.
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.Climacteric2014;
17: 252–259.
27.
GoodwinPJEnnisMPritchardKIet al.
Risk of menopause during the first year after breast cancer diagnosis.J Clin Oncol1999;
17: 2365–2370.
28.
PetrekJANaughtonMJCaseLDet al.
Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study.J Clin Oncol2006;
24: 1045–1051.
29.
RunowiczCDLeachCRHenryNLet al.
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.J Clin Oncol2016;
34: 611–635.
30.
LambertiniMDel MastroLPescioMCet al.Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med2016;
14: 1–16.
31.
SukumvanichPCaseLDKimberly Van ZeeKet al.
Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment a prospective study.Cancer2010;
116: 3102–3011.
32.
ZhangYJiYLiJet al.
Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.Breast Cancer Res Treat2018;
168: 679–686.
33.
ShandleyLMSpencerJBFothergillAet al.
Impact of tamoxifen therapy on fertility in breast cancer survivors.Fertil Steril2017;
107: 243–252.e5.
34.
LambertiniMMooreHCFLeonardRCFet al.
Gonadotrophin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data.J Clin Oncol2018;
36: 1981–1990.
35.
NICE. Fertility problems: assessment and treatment. NICE guidelines [CG156], February 2013, www.NICE.org.uk(accessed 18 January 2019).
36.
YasminEBalachandrenNDaviesMCet al.
Fertility preservation for medical reasons in girls and women: British fertility society policy and practice guideline.Hum Fertil2018;
21: 3–26.
37.
MarsdenJ.Hormonal contraception and breast cancer, what more do we need to know?Post Reprod Health2017;
23: 116–127.
38.
NICE. Menopause: diagnosis and management. NICE guidelines [NG23], November 2015, www.NICE.org.uk(accessed 18 January 2019).
39.
LonningPEJohannessenDCLienEAet al.
Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients.J Steroid Biochem Mol Biol1995;
52:491–496.
40.
CockshottID.Clinical pharmacokinetics of goserelin.Clin Pharmacokinet2000;
39:27–48.
41.
AndersonRAMansiJColemanREet al.
The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.Eur J Cancer2017;
87: 58–64
42.
IwaseANakamuraTNakaharaTet al.
Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review. Reprod Sci2015;
22: 519–526.
43.
Position Statement:
Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause2015;
22: 1155–1174.
44.
JohnsCSeavSMDominickSAet al.
Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions.Breast Cancer Res Treat2016;
156:415–426.
45.
MarshM.Hormones, damned hormones and statistics.BJOG2017;
124: 1465–1466.
46.
SarriGPedderHDiasSet al.
Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause.BJOG2017;
124: 1514–1523.
47.
RadaGCapurroDPantojaTet al.
Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev2010; (9): CD004923.
48.
StuenkelCADavisSRGompelA.Treatment of symptoms of menopause: an endocrine society practice guideline. J Clin Endocrinol Metab2015;
100: 3975–4011.
49.
PanayN; on behalf of the British Menopause Society. BMS consensus statement: bioidentical hormones, September 2017, www.thebmw.org.uk(accessed 18 January 2019).
50.
van DrielCMGStuursmaASSchroeversMJet al.Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis. BJOG2019;
126:330–339.
51.
ShermanBMChaplerFKCrickardKet al.
Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest1979;
64: 398–404.
52.
CuzickJSestakICawthornSet al.
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.Lancet Oncol2015;
16: 67–75.
53.
Committee on Practice Bulletins-Gynecology.ACOG Practice Bulletin No. 126: management of gynecologic issues in women with breast cancer. Obstet Gynecol2012;
119: 666–682.
54.
FaubionSSLarkinLCStuenkelCAet alNAMS Consensus Recommendations. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause2018;
25: 596–608.
55.
EdwardsDPanayN.Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?Climacteric2016;
19: 151–161.
56.
SimonJAAltomareCCortSet al.
Overall safety of Ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials.J Womens Health2018;
27: 14–23.
BecorpiACampiscianoGZanottaNet al.
Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspectsLasers Med Sci2018;
33: 1047–1054.
60.
GambaccianiMLevancinM.Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors.Menopause2017;
24: 316–319.
61.
BartonDLSloanJAShusterLTet al.
Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance).Support Care Cancer2018,
26: 643–650.
62.
BartonDLShusterLTDockterTet al.
Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Care Cancer2018;
26: 1335–1343.
63.
YangGSKimHJGriffithKAet al.
Interventions for the treatment of aromatase inhibitor-associated arthralgia in breast cancer survivors: a systematic review and meta-analysis.Cancer Nurs2017;
40: E26–E41.
64.
HenryNLUngerJMSchottAFet al.Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202.J Clin Oncol2018;
36:326–332.
65.
MannESmithMJHellierJet al.
Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial.Lancet Oncol2012;
13: 309–318.
66.
NahmNMeeSMarxG.Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review. Asia Pac J Clin Oncol2018;
14:374–382.
67.
MoralesLPansSParidaensRet al.Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat2007;104: 87–91.
68.
NiravathP.Aromatase inhibitor-induced arthralgia: a review.Ann Oncol2013;
24: 1443–1449.
69.
ThorneC.Management of arthralgias associated with aromatase inhibitor therapy.Curr Oncol2007;
14: S11–S19.
70.
YounusJKligmanL.Management of aromatase inhibitor-induced arthralgia.Curr Oncol2010;
17: 87–90.
71.
MenasPMerkelDHuiWet al.
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.J Oncol Pharm Pract2012;
18:387–393.
72.
BriotKTubiana-HulinMBastitLet al.
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.Breast Cancer Res Treat2010;
120:127–134.
73.
KadakiaKCKidwellKMSeewaldNJet al.
Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.Breast Cancer Res Treat2017;
164: 411–419.
74.
HolmbergLIversonOERudenstamCMet al.
Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.JNCI2008;
100: 475–
482.
75.
FahlénMFornanderTJohanssonHet al.Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer2013;
49: 52–59.
76.
MarsdenJMordenJA’HernRet al.;on behalf of the UK HRT Trial Management Group. Hormone replacement therapy (HRT) is effective in relieving estrogen deficiency symptoms (ODS) and improves quality of life in breast cancer patients: the UK randomised HRT trial experience.Maturitas2017;
100: 132.
77.
Vassilopoulou-SellinRVassilopoulou-SellinRTheriaultRLet al.
Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer.Gynecol Oncol1997;
65: 89–93.
78.
O'MearaESRossingMADalingJRet al.
Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality.J Natl Cancer Inst2001;
93: 754–762.
79.
DurnaEMWrenBGHellerGZet al.
Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust2002;
177: 347–351.
80.
DewJEWrenBGEdenJA.Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. Climacteric2002:
5: 151–155.
81.
DewJEWrenBGEdenJA.A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer,Climacteric2003;
6: 45–52.
82.
Le RayIDell'AnielloSBonnetainFet al.
Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.Breast Cancer Res Treat2012;
135:603–
609.
83.
KenemansPBundredNJFoidartJMet al.; LIBERATE Study group.
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.Lancet Oncol2009;
10: 135–
146.
84.
NICE. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. Clinical guideline [CG164], June 2013, www.nice.org.uk(accessed 18 January 2019).
85.
ColleoniMSunZPriceKNet al.Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. J Clin Oncol2016;
34: 927–
935.
86.
LowerEEKhanSKennedyDet al.Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site. Breast Cancer2017;
9: 515–
552.
87.
MezencevMŠvajdlerM.Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries. Breast Cancer2017;
24: 400–410.
88.
SestakIKealyREdwardsRet al.
Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.J Clin Oncol2006;
24: 3991–3996.
89.
FahlenMWallbergBvon SchoultzEet al.
Health-related quality of life during hormone therapy after breast cancer: a randomized trial.Climacteric2011;
14: 164–170.
